Related Experiment Videos
Interferons in oncology
1Department of Clinical Oncology, University of Nottingham.
Abstract:
The interferons are natural glycoproteins secreted in response to various stimuli, including viral infection. They have antiviral, antiproliferative and immunomodulatory effects on different target cell populations. Since recombinant human interferons have become available, they have been tested in a wide range of malignancies. They are well established in the treatment of hairy cell leukaemia, chronic myelogenous leukaemia and multiple myeloma. Although they have documented activity against lymphoma, melanoma, renal cell cancer and carcinoid tumours, their role in the treatment of these tumours is less clear. In the common solid tumours, such as lung cancer and colorectal cancer, the use of interferons remains experimental. Here we will summarise their practice applications in oncology, using randomised studies where available to establish their place in multi-modality treatment. We will not discuss their use as antiviral or immunomodulating agents in viral and autoimmune diseases, multiple sclerosis or after organ transplantation.
Insights
Interferons, glycoproteins with antiviral effects, are established treatments for certain leukemias and myeloma. Their use in solid tumors like lung and colorectal cancer remains experimental, with ongoing research into multi-modality treatment applications.
Area of Science:
- Oncology
- Immunology
- Biochemistry
Background:
- Interferons are natural glycoproteins with antiviral, antiproliferative, and immunomodulatory properties.
- Recombinant human interferons are utilized in treating various malignancies.
- Established efficacy in hairy cell leukemia, chronic myelogenous leukemia, and multiple myeloma.
Purpose of the Study:
- To summarize the clinical applications of interferons in oncology.
- To evaluate the role of interferons in multi-modality cancer treatment.
- To review randomized studies on interferon efficacy in malignancies.
Main Methods:
- Review of randomized clinical trials and practice applications.
- Focus on oncological uses, excluding antiviral and immunomodulatory roles in non-cancer diseases.
- Synthesis of evidence for interferon's place in cancer therapy.
Main Results:
- Interferons are well-established for hematologic malignancies like leukemia and myeloma.
- Documented activity in lymphoma, melanoma, renal cell cancer, and carcinoid tumors, though role is less clear.
- Use in common solid tumors (lung, colorectal cancer) is still experimental.
Conclusions:
- Interferons have a defined role in specific hematologic cancers.
- Further research is needed to clarify their utility in solid tumors and as part of multi-modality treatment regimens.
- The application of interferons in oncology is evolving, with ongoing investigation into their therapeutic potential.